Mycophenolate mofetil: A possible therapeutic agent for children with juvenile dermatomyositis

Abstract

MMF appears to be worthy of consideration as an additional therapeutic modality for treatment of children with juvenile DM. These data suggest that the use of MMF decreases skin and muscle disease activity and is steroid sparing. MMF appears to be well tolerated, but patients should be monitored for infection.